卵巢癌患者血清VEGF、CA125的表达及其与疾病进展的关系

Expression of VEGF, CA125 in the serum of patents with ovarian cancer and its relationship with disease progression

目的探讨血管内皮细胞生长因子(VEGF)和糖类抗原(CA125)在卵巢癌患者血清中的表达及其与疾病进展的关系。方法检测50例卵巢癌患者、50例卵巢良性疾病患者和60例健康女性血清中VEGF、CA125的水平,将卵巢癌患者以有无淋巴结转移分为两组,同时按FIGO(1987年)进行临床分期:Ⅰ期10例、Ⅱ期18例、Ⅲ期12例,Ⅳ期10例;用酶联法检测VEGF,用电化学发光法检测CA125。结果卵巢癌组各项检测指标与良性疾病组和正常对照组比较差异均有统计学意义(P<0.01),而良性组与健康对照组比较VEGF差异无统计学意义(P>0.05),CA125差异有统计学意义(P<0.01);卵巢癌患者有无淋巴结转移血清VEGF、CA125水平比较差异均有统计学意义(P<0.01);不同临床分期卵巢癌患者血清VEGF、CA125水平比较,Ⅳ期与Ⅲ期,Ⅲ期与Ⅰ、Ⅱ期比较VEGF、CA125水平差异均有统计学意义(P<0.01)。结论联合检测血清VEGF、CA125对卵巢癌的诊断、病情评估以及预后判断具有重要价值。

Objective To study the expression of vascular endothelial growth factor （VEGF）, carbohydrate antigen （CA-125） in the serum of patents with ovarian cancer, and to investigate the relationship between VEGF, CA125 expression and disease progression of ovarian cancer. Methods The levels of VEGF and CA125 were detected 50 patients with ovarian cancer, 50 patients with benign ovarian diseases and 60 healthy women. The patients with ovarian cancer were divided into two groups according to lymphnode metastasis and into four periods according to FIGO （1987）： 10 cases of Ⅰ period, 18 cases of Ⅱ period, 12 cases of Ⅲ period, 10 cases of Ⅳ period. The levels of VEGF were detected by ELISA, and the levels of CA125 were detected by chemoluminescence. Results The levels of VEGF and CA125 in the patients with ovarian cancer showed statistically significant difference with those in the patients with benign ovarian diseases and the healthy women （P〈0.01）. The levels of VEGF showed no statistically significant difference between the patients with benign ovarian diseases and the healthy women （P〈0.05）, while the levels of CA125 showed statistically significant difference （P〈0.01）. There was statistically significant difference in the levels of VEGF and CA125 between Ⅳ period and Ⅲ period, between Ⅲ period and Ⅰ, Ⅱperiod （P〈0.01）. There was statistically significant difference the levels of VEGF and CA125 between the patients with or without lymphnode metastasis （P〈0.01）. Conclusion Combined detection of VEGF, CA125 in serum can be used as an important reference index for the diagnosis of ovarian cancer, the evaluation of disease situation and prognosis.